Synergy CHC Appoints Pedro Colmenares as Sales & Marketing Director for Mexico & Latin America
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 16 2025
0mins
Should l Buy SNYR?
Synergy CHC announced that Pedro Colmenares has been appointed Director of Sales & Marketing for Mexico & Latin America. In this role, Mr. Colmenares will lead commercial strategy, market expansion, and go-to-market execution across the region. Colmenares is a senior commercial executive with over 18 years of experience across the pharmaceutical, nutraceutical, OTC, and consumer health sectors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SNYR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SNYR
Wall Street analysts forecast SNYR stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.210
Low
5.00
Averages
6.00
High
7.00
Current: 1.210
Low
5.00
Averages
6.00
High
7.00
About SNYR
Synergy CHC Corp. is a provider of consumer healthcare, beauty, and lifestyle products. The Company's brand portfolio includes FOCUSfactor and Flat Tummy. FOCUSfactor is a clinically studied brain health supplement and functional beverage line. Flat Tummy is a lifestyle brand that provides a suite of nutritional products to help women achieve their weight management goals. It has six additional, non-core brands are Hand MD is a complete hand-care brand to help maintain clean and healthy hands while reducing the signs of aging; Perfekt Beauty is in beauty line of products for the eyes, lips, brows, cheeks and skin; Sneaky Vaunt is in lingerie brand with a line of women’s shapewear, bralettes and panties; The Queen Pegasus is in eyelash enhancement products for longer, thicker, natural lashes; Neuragen is in fast-acting topical treatments for neuropathic (nerve) pain, and UrgentRx is in line of fast-acting, portable, powdered over-the-counter medications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Synergy CHC Corp. Updates Q4 and Full Year 2025 Financial Results Release Date
- Financial Reporting Schedule: Synergy CHC Corp. will release its fourth quarter and full year financial results for the period ending December 31, 2025, on April 1, 2026, before market open, ensuring timely access to critical financial information for investors.
- Conference Call Details: The company's CEO Jack Ross and CFO Jaime Fickett will host a conference call at 9:00 a.m. ET to provide detailed insights into the financial results, enhancing communication with investors.
- Webcast Availability: The conference call will be available via a live webcast on the company's Investor Relations section, allowing investors who cannot dial in to participate, thereby improving information transparency.
- Brand Market Performance: Synergy's brands, FOCUSfactor® and Flat Tummy®, continue to grow in major retailers across the U.S., Canada, Mexico, and the U.K., demonstrating the company's strong competitive position in the health and wellness product market.
See More
New Show to Air Tonight on Bloomberg Television
- Global Broadcast Expansion: New to The Street's latest episode will air tonight at 6:30 PM EST on Bloomberg Television, extending its reach to the U.S., MENA, and Latin America, thereby enhancing international investor engagement and broadening its audience base.
- Biotech Advancements: BioVie Inc. is advancing a clinical trial for Parkinson's disease with 60 patients enrolled, expecting topline data in May 2026, which could significantly bolster its market position in the biopharmaceutical sector if successful.
- Obstructive Sleep Apnea Solutions: Vivos Therapeutics Inc.'s FDA-cleared non-surgical oral appliance aims to provide a long-term solution for the estimated one billion people affected by OSA globally, with strategic growth initiatives targeting direct-to-patient markets.
- Virtual Reality Market Growth: Virtuix Holdings Inc.'s Omni One platform has reported a 138% year-over-year growth in the gaming and fitness sectors, with production capacity supporting potential annual revenues of up to $100 million, indicating strong demand in both consumer and defense markets.
See More
New Show Airing on Bloomberg Television
- Rich Program Content: Tonight's airing of 'New to The Street' on Bloomberg Television will showcase Virtuix's immersive technology platform, highlighting its rapid growth in consumer and defense markets, which is expected to attract a wide audience.
- International Expansion Update: YY Group will provide updates on its international expansion in Hong Kong, UAE, and Southeast Asia, showcasing AI-enabled workforce automation and strong revenue momentum, indicating its competitiveness in the premium client market.
- Strategic Acquisition Discussion: Roadzen's leadership will discuss its strategic acquisition plans and the scaling of its AI-driven auto insurance and claims ecosystem, demonstrating its innovative capabilities and market potential in the insurance industry.
- Fintech Strategy: Alphaton Capital will outline its fintech-driven investment strategy and capital markets positioning in an interview filmed at the New York Stock Exchange, enhancing its credibility and appeal among global investors.
See More
New to The Street Broadcasts Show #716 Featuring SDST and Others
- Broadcast Timing: New to The Street will air Show #716 tonight at 6:30 PM Eastern Time on Bloomberg Television, enhancing its influence in the business media landscape by showcasing various public companies.
- Company Highlights: The episode will spotlight Stardust Power Inc. (NASDAQ:SDST), BioVie Inc. (NASDAQ:BIVI), and Roadzen Inc. (NASDAQ:RDZN), showcasing innovations in critical minerals, biotechnology, and AI-driven mobility and insurance solutions, aimed at attracting investor interest.
- Celebrity Features: The show will also include special segments with Kelsey Grammer discussing his new book KAREN and Andrew Shaw introducing his nonprofit 250DAYS.ORG, emphasizing the importance of mental health awareness and recovery, thereby enhancing the program's social impact.
- International Expansion Plans: New to The Street plans to launch its international version in the MENA region on January 24, 2026, further expanding its global reach, while also preparing to launch the Spanish-language platform Nuevo En La Calle, showcasing its diversified media strategy.
See More
New to The Street Highlights Blockchain and Oncology Innovations in Episode #710
- Blockchain Infrastructure Acceleration: TokenFI's Chief Revenue Officer Pedro Vidal discussed strategies for accelerating institutional adoption of blockchain tokenization, aiming to build scalable, compliance-ready infrastructure for real asset issuance, which is expected to drive transformation in financial markets.
- New Oncology Treatment Platform: NeOnc Technologies' CEO Amir Heshmatpour introduced an intranasal drug delivery platform targeting aggressive brain cancers along with its clinical and regulatory roadmap, potentially providing new treatment options and improving survival rates for patients.
- AI-Driven Drug Discovery: Lantern Pharma's CEO Panna Sharma outlined their AI-driven approach to oncology drug discovery, enhancing research speed and capital efficiency, which is anticipated to increase clinical success rates and expedite new drug market entry.
- Infrastructure Investment Strategy: Mataterra Holdings' co-chairmen Monika Proffitt and Douglas Anderson provided strategic insights on global infrastructure development and real asset tokenization, emphasizing the importance of capital formation to meet future market demands.
See More
Synergy CHC Appoints Pedro Colmenares as Sales Director for Mexico & Latin America
- Market Expansion Strategy: Synergy CHC has appointed Pedro Colmenares as Director of Sales and Marketing for Mexico and Latin America, aiming to leverage his extensive experience to drive market expansion in the region, particularly in the supplement and functional beverage sectors.
- New Subsidiary Formation: The company established a wholly owned subsidiary in Mexico in May 2025 and began shipments to Costco Mexico this week, marking its initial market entry and laying the groundwork for future sales growth.
- Rich Leadership Experience: Colmenares brings over 18 years of industry experience from roles at Procter & Gamble and Victus/Megalabs, which will aid Synergy in building scalable commercial platforms and driving sustainable growth in Latin America.
- Brand Development Potential: The success of the FOCUSfactor brand in the U.S., Canada, and the U.K. provides a strong market foundation for Synergy, and combined with Colmenares' localized execution capabilities, significant growth in the Latin American market is anticipated.
See More
Synergy CHC Corp. Updates Q4 and Full Year 2025 Financial Results Release Date
- Financial Reporting Schedule: Synergy CHC Corp. will release its fourth quarter and full year financial results for the period ending December 31, 2025, on April 1, 2026, before market open, ensuring timely access to critical financial information for investors.
- Conference Call Details: The company's CEO Jack Ross and CFO Jaime Fickett will host a conference call at 9:00 a.m. ET to provide detailed insights into the financial results, enhancing communication with investors.
- Webcast Availability: The conference call will be available via a live webcast on the company's Investor Relations section, allowing investors who cannot dial in to participate, thereby improving information transparency.
- Brand Market Performance: Synergy's brands, FOCUSfactor® and Flat Tummy®, continue to grow in major retailers across the U.S., Canada, Mexico, and the U.K., demonstrating the company's strong competitive position in the health and wellness product market.
See More
New Show to Air Tonight on Bloomberg Television
- Global Broadcast Expansion: New to The Street's latest episode will air tonight at 6:30 PM EST on Bloomberg Television, extending its reach to the U.S., MENA, and Latin America, thereby enhancing international investor engagement and broadening its audience base.
- Biotech Advancements: BioVie Inc. is advancing a clinical trial for Parkinson's disease with 60 patients enrolled, expecting topline data in May 2026, which could significantly bolster its market position in the biopharmaceutical sector if successful.
- Obstructive Sleep Apnea Solutions: Vivos Therapeutics Inc.'s FDA-cleared non-surgical oral appliance aims to provide a long-term solution for the estimated one billion people affected by OSA globally, with strategic growth initiatives targeting direct-to-patient markets.
- Virtual Reality Market Growth: Virtuix Holdings Inc.'s Omni One platform has reported a 138% year-over-year growth in the gaming and fitness sectors, with production capacity supporting potential annual revenues of up to $100 million, indicating strong demand in both consumer and defense markets.
See More
New Show Airing on Bloomberg Television
- Rich Program Content: Tonight's airing of 'New to The Street' on Bloomberg Television will showcase Virtuix's immersive technology platform, highlighting its rapid growth in consumer and defense markets, which is expected to attract a wide audience.
- International Expansion Update: YY Group will provide updates on its international expansion in Hong Kong, UAE, and Southeast Asia, showcasing AI-enabled workforce automation and strong revenue momentum, indicating its competitiveness in the premium client market.
- Strategic Acquisition Discussion: Roadzen's leadership will discuss its strategic acquisition plans and the scaling of its AI-driven auto insurance and claims ecosystem, demonstrating its innovative capabilities and market potential in the insurance industry.
- Fintech Strategy: Alphaton Capital will outline its fintech-driven investment strategy and capital markets positioning in an interview filmed at the New York Stock Exchange, enhancing its credibility and appeal among global investors.
See More
New to The Street Broadcasts Show #716 Featuring SDST and Others
- Broadcast Timing: New to The Street will air Show #716 tonight at 6:30 PM Eastern Time on Bloomberg Television, enhancing its influence in the business media landscape by showcasing various public companies.
- Company Highlights: The episode will spotlight Stardust Power Inc. (NASDAQ:SDST), BioVie Inc. (NASDAQ:BIVI), and Roadzen Inc. (NASDAQ:RDZN), showcasing innovations in critical minerals, biotechnology, and AI-driven mobility and insurance solutions, aimed at attracting investor interest.
- Celebrity Features: The show will also include special segments with Kelsey Grammer discussing his new book KAREN and Andrew Shaw introducing his nonprofit 250DAYS.ORG, emphasizing the importance of mental health awareness and recovery, thereby enhancing the program's social impact.
- International Expansion Plans: New to The Street plans to launch its international version in the MENA region on January 24, 2026, further expanding its global reach, while also preparing to launch the Spanish-language platform Nuevo En La Calle, showcasing its diversified media strategy.
See More
New to The Street Highlights Blockchain and Oncology Innovations in Episode #710
- Blockchain Infrastructure Acceleration: TokenFI's Chief Revenue Officer Pedro Vidal discussed strategies for accelerating institutional adoption of blockchain tokenization, aiming to build scalable, compliance-ready infrastructure for real asset issuance, which is expected to drive transformation in financial markets.
- New Oncology Treatment Platform: NeOnc Technologies' CEO Amir Heshmatpour introduced an intranasal drug delivery platform targeting aggressive brain cancers along with its clinical and regulatory roadmap, potentially providing new treatment options and improving survival rates for patients.
- AI-Driven Drug Discovery: Lantern Pharma's CEO Panna Sharma outlined their AI-driven approach to oncology drug discovery, enhancing research speed and capital efficiency, which is anticipated to increase clinical success rates and expedite new drug market entry.
- Infrastructure Investment Strategy: Mataterra Holdings' co-chairmen Monika Proffitt and Douglas Anderson provided strategic insights on global infrastructure development and real asset tokenization, emphasizing the importance of capital formation to meet future market demands.
See More
Synergy CHC Appoints Pedro Colmenares as Sales Director for Mexico & Latin America
- Market Expansion Strategy: Synergy CHC has appointed Pedro Colmenares as Director of Sales and Marketing for Mexico and Latin America, aiming to leverage his extensive experience to drive market expansion in the region, particularly in the supplement and functional beverage sectors.
- New Subsidiary Formation: The company established a wholly owned subsidiary in Mexico in May 2025 and began shipments to Costco Mexico this week, marking its initial market entry and laying the groundwork for future sales growth.
- Rich Leadership Experience: Colmenares brings over 18 years of industry experience from roles at Procter & Gamble and Victus/Megalabs, which will aid Synergy in building scalable commercial platforms and driving sustainable growth in Latin America.
- Brand Development Potential: The success of the FOCUSfactor brand in the U.S., Canada, and the U.K. provides a strong market foundation for Synergy, and combined with Colmenares' localized execution capabilities, significant growth in the Latin American market is anticipated.
See More
